Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric IV oritavancin versus standard of care for acute bacterial skin and skin structure infections
2022-001297-63Phase 2Active
- Sponsor
- Melinta Therapeutics
- Start
- Jan 2023
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of oritavancin and levothyroxine sodium in acute bacterial skin and skin structure infection (ABSSSI) (2 arms), sponsored by Melinta Therapeutics. Primary endpoint: Safety assessment of ORBACTIV and KIMYRSA in pediatric populations. Started Jan 2023; status: active.
02
Drugs
oritavancinlevothyroxine sodium
03
Conditions
acute bacterial skin and skin structure infection (ABSSSI)
Beyond the preview
Go deeper on 2022-001297-63.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001297-63.